Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
51 hedge funds and large institutions have $42.2M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 4 closing their positions.
271% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $421K
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
51% more capital invested
Capital invested by funds: $27.9M → $42.2M (+$14.3M)
16% more funds holding
Funds holding: 44 → 51 (+7)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.77M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.61M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.19M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$976K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GF
Gabelli Funds
Rye,
New York
|
-$875K |
| 2 |
MERSOM
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
|
-$829K |
| 3 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
-$712K |
| 4 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$704K |
| 5 |
BAMS
Bellevue Asset Management (Switzerland)
Kuesnacht,
Switzerland
|
-$663K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAM
51
Oxford Asset Management
Oxford,
United Kingdom
| – | -$303K | -33,107 | Closed |
|
52
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$74K | -8,161 | Closed |
|
|
PCM
53
Prelude Capital Management
New York
| – | -$3K | -300 | Closed |
|
54
Group One Trading
Chicago,
Illinois
| – | -$2.24K | -203 | Closed |
|
JNP Hedge Fund Activity: Q3 2015 in Review
51 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2015, worth a combined $42.2M — up 51% from $27.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new JNP positions and 4 closed out — a net gain of 7 holders — while 14 added to existing stakes and 17 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.77M. The largest seller was Gabelli Funds, cutting an estimated $875K.
- 51 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2015, up from 44 in Q2 2015.
- Funds reported $42.2M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2015, up 51% quarter-over-quarter.
- 11 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2015 and 4 closed out, a net change of +7 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q3 2015 was Morgan Stanley, an estimated $2.77M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2015 was Gabelli Funds, an estimated $875K sold.
Based on aggregated 13F filings for Q3 2015.